A Prospective, Controlled, Double Blind, Single Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs B 244 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors AOBiome
- 21 Mar 2018 According to an AOBiome media release, company has announced clinical findings from Part 1, and has initiated Part 2 of this trial.
- 03 Oct 2017 Status changed from not yet recruiting to recruiting, according to an AOBiome media release.
- 25 Sep 2017 New trial record